無料プレビュー

Insmed Incorporated (INSM) · NASDAQ Global Select

プロフィール

Insmed Inc is a global biopharmaceutical company developing therapies across three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company commercializes ARIKAYCE (amikacin liposome inhalation suspension) for MAC lung disease and BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, with an advanced clinical pipeline including TPIP for pulmonary hypertension and gene therapies for rare neurological diseases. Products are marketed globally, with approved indications in the US, EU, and Japan, supported by proprietary inhalation delivery technology

主要指標

株価: $100.48 (-1.24%)
時価総額: 218億ドル
PER（今期予想）: -62.0
PBR: 28.8
配当利回り: —
52週レンジ: $90.39 – $212.75
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-29 · 更新: 2026-10-09